H2 Receptor Antagonist

DRUG5 trials

Conditions

Colorectal Cancer (CRC)Dedifferentiated LiposarcomaEsophageal Squamous Cell CarcinomaFallopian Tube CancerGastric / Gastroesophageal Junction AdenocarcinomaGastric Cancer (GC)Gastric Cancer Adenocarcinoma MetastaticHNSCC

Phase 1

A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)

RecruitingNCT05319730

Merck Sharp & Dohme LLCEsophageal Squamous Cell Carcinoma

Start: 2023-05-16End: 2029-04-10Target: 230Updated: 2026-06-26

A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors

RecruitingNCT06789172

EpkinColorectal Cancer (CRC), Dedifferentiated Liposarcoma, Gastric Cancer Adenocarcinoma Metastatic +12

Start: 2025-01-23End: 2028-09-01Target: 146Updated: 2026-06-11

Phase 2

Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)

RecruitingNCT06788912

Merck Sharp & Dohme LLCLung Neoplasm Malignant

Start: 2025-03-20End: 2032-02-06Target: 60Updated: 2026-06-26

Phase 3

Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

Active, not recruitingNCT06305754

Merck Sharp & Dohme LLCNon-small Cell Lung Cancer (NSCLC)

Start: 2024-06-11End: 2030-06-14Target: 520Updated: 2026-07-06

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

RecruitingNCT06824467

Merck Sharp & Dohme LLCFallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cancer

Start: 2025-04-09End: 2032-11-09Target: 770Updated: 2026-07-10

Journal of Clinical Oncology2026-05-28

Updated design of INVOKE: A phase 1 study of OKN4395, a first-in-class EP2/EP4/DP1 triple prostanoid receptor antagonist, in patients with advanced solid tumors.

Journal of Clinical Oncology2026-05-28

Feasibility of constructing an external control arm for early efficacy assessment in phase 1a: Methodological framework from the INVOKE trial.

Journal of Clinical Oncology2026-05-27

OKN4395, a first-in-class EP2/EP4/DP1 triple antagonist reprograms prostanoid-driven immunosuppression to restore antitumor immunity

2026-02-10

Sacituzumab tirumotecan versus docetaxel for previously treated <i>EGFR</i> -mutated advanced non-small cell lung cancer: multicentre, open label, randomised controlled trial

BMJ2025-06-0514 citations

INVOKE: A phase 1 study of OKN4395, a first-in-class EP2/EP4/DP1 triple prostanoid receptor antagonist, in patients with advanced solid tumors.

Journal of Clinical Oncology2025-05-28

KEYMAKER-U01E: A phase 2 umbrella study with rolling arms of investigational agents with or without chemotherapy plus pembrolizumab for resectable stage II–IIIB (N2) non–small-cell lung cancer (NSCLC).